The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome

Hypertension Research

Volumn 37, Issue 7, 2014, Pages 629-635

  Nakagami, Hironori ^a   Pang, Zhengda ^a   Shimosato, Takashi ^b   Moritani, Toshinori ^b   Kurinami, Hitomi ^a   Koriyama, Hiroshi ^a   Tenma, Akiko ^a   Shimamura, Munehisa ^a   Morishita, Ryuichi ^c  

^a OSAKA UNIVERSITY   (Japan)

^b Nissei Bilis Co Ltd   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

DPP 4 inhibitor; endothelial function; insulin resistance; SHRcp

Indexed keywords

ACETYLCHOLINE; DIPEPTIDYL PEPTIDASE IV; GLUCOSE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN RECEPTOR; NITRIC OXIDE SYNTHASE; TENELIGLIPTIN; TUMOR NECROSIS FACTOR ALPHA; VASODILATOR AGENT; 3-(4-(4-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)PIPERAZIN-1-YL)PYRROLIDIN-2-YLCARBONYL)THIAZOLIDINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PYRAZOLE DERIVATIVE; THIAZOLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HEART RATE; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LONG TERM CARE; METABOLIC SYNDROME X; NONHUMAN; NONSENSE MUTATION; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHENOTYPE; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; UPREGULATION; WISTAR KYOTO RAT; AGING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

AGING; ANIMALS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GLUCOSE; INSULIN RESISTANCE; METABOLIC SYNDROME X; PYRAZOLES; RATS; RATS, INBRED SHR; THIAZOLIDINES;

EID: 84904902508     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2014.53     Document Type: Article

References (24)

1. Garrison RJ, Kannel WB, Stokes J 3rd, Castelli WP. Incidence and precursors of hypertension in young adults: The Framingham Offspring Study. Prev Med 1987; 16: 235-251.
2. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens 1995; 13: 1457-1462.
3. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Imparied nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Col Cardiol 1996; 27: 567-574.
4. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, Stuehlinger M, Tsao PS. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 1201-1203.
5. Chiu JD, Richey JM, Harrison LN, Zuniga E, Kolka CM, Kirkman E, Ellmerer M, Bergman RN. Direct administration of insulin into skeletal muscle reveals that the transport of insulin across the capillary endothelium limits the time course of insulin to activate glucose disposal. Diabetes 2008; 57: 828-835.
6. Barrett EJ, Eggleston EM, Inyard AC, Wang H, Li G, Chai W, Liu Z. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia 2009; 52: 752-764.
7. Kubota T, Kubota N, Kumagai H, Yamaguchi S, Kozono H, Takahashi T, Inoue M, Itoh S, Takamoto I, Sasako T, Kumagai K, Kawai T, Hashimoto S, Kobayashi T, Sato M, Tokuyama K, Nishimura S, Tsunodam M, Idem T, Murakami K, Yamazaki T, Ezaki O, Kawamura K, Masuda H, Moroi M, Sugi K, Oike Y, Shimokawa H, Yanagihara N, Tsutsui M, Terauchi Y, Tobe K, Nagai R, Kamata K, Inoue K, Kodama T, Ueki K, Kadowaki T. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 2011; 13: 294-307.
8. Holst JJ. Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors. Adv Exp Med Biol 2003; 524: 263-279.
9. Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2003; 12: 87-100.
10. Takaya K, Ogawa Y, Hiraoka J, Hosoda K, Yamori Y, Nakao K, Koletsky RJ. Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat Genet 1996; 14: 130-131.
11. Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007; 50: 877-883.
12. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, Fujita T. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006; 17: 3438-3446.
13. Sueta D, Nakamura T, Dong YF, Kataoka K, Koibuchi N, Yamamoto E, Toyama K, Yasuda O, Ogawa H, Kim-Mitsuyama S. Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. Am J Hypertens 2012; 25: 704-710.
14. Hayashi K, Nakamura S, Morishita R, Moriguchi A, Aoki M, Matsumoto K, Nakamura T, Kaneda Y, Sakai N, Ogihara T. In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther 2000; 7: 1664-1671.
15. Van Poppel PC, Netea MG, Smits P, Tack CJ. Vidagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care 2011; 34: 2072-2077.
16. Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, Ogawa H. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J 2013; 77: 1337-1344.
17. Kubota Y, Miyamoto M, Takagi G, Ikeda T, Kirinoki-Ichikawa S, Tanaka K, Mizuno K. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci 2012; 27: 1364-1370.
18. Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohba K, Konishi M, Maeda H, Izumiya Y, Kaikita K, Sumida H, Jinnouchi H, Matsui K, Kim-Mitsuyama S, Takeya M, Ogawa H. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 2012; 59: 265-276.
19. Nabeno M, Akahoshi F, Kishida H, Miyaguchi I, Tanaka Y, Ishii S, Kadowaki T. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun 2013; 434: 191-196.
20. Kimata H, Fukuda-Tsuru S, Yoshida K, Iwasaki S, Kiuchi S, Akahoshi F, Ishii S. Teneligliptin, a novel selective dipeptidyl peptidase-4 inhibitor, improves postprandial hyperglycemia in a model of type 2 diabetes, zucker diabetic fatty rats. Med Consult New Remedies 2012; 49: 9.
21. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 2009; 54: 516-523.
22. Guan X, Karpen HE, Stephens J, Bukowski JT, Niu S, Zhang G, Stoll B, Finegold MJ, Holst JJ, Hadsell D, Nichols BL, Burrin DG. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006; 130: 150-164.
23. Huang CY, Shih CM, Tsao NW, Lin YW, Huang PH, Wu SC, Lee AW, Kao YT, Chang NC, Nakagami H, Morishita R, Ou KL, Hou WC, Lin CY, Shyu KG, Lin FY. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. Br J Pharmacol 2012; 167: 1506-1519.
24. Fadini GP, Agostini C, Sartore S, Avogaro A. Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis 2007; 194: 46-54.